A Study to Assess the Safety, Tolerability, and Pharmacokinetics of ABSK-021 in Patients With Advanced Solid Tumor

PHASE1RecruitingINTERVENTIONAL
Enrollment

276

Participants

Timeline

Start Date

January 20, 2020

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2026

Conditions
NeoplasmsTenosynovial Giant Cell Tumor
Interventions
DRUG

ABSK021

ABSK021 oral capsule

Trial Locations (17)

30322

COMPLETED

The Winship Cancer Institute of Emory University, Atlanta

77030

COMPLETED

MD Anderson Cancer Center, Houston

90212

RECRUITING

Precision NextGen Oncology, Beverly Hills

80218-1238

COMPLETED

SCRI at HealthOne, Denver

Unknown

RECRUITING

Beijing Jishuitan Hospital, Beijing

RECRUITING

The First Affiliated Hospital of Sun Yat-sen University, Guangdong

COMPLETED

Hebei Medical University Third Hospital, Shijiazhuang

RECRUITING

Henan Cancer Hospital, Zhengzhou

COMPLETED

The First Affiliated Hospital of Zhengzhou Universtity, Zhengzhou

ACTIVE_NOT_RECRUITING

Jiangsu Province Hospital, Nanjing

RECRUITING

Nanjing Drum Tower Hospital, Nanjing

COMPLETED

Liaoning Cancer Hospital, Shenyang

COMPLETED

Huashan Hospital of Fudan University, Shanghai

COMPLETED

Shanghai Sixth People's Hospital, Shanghai

RECRUITING

Xi'an Hong Hui Hospital, Xian

RECRUITING

West China Hospital of Sichuan University, Chengdu

RECRUITING

The Second Affiliated Hospital Zhejiang University School of Medicine, Hangzhou

Sponsors
All Listed Sponsors
lead

Abbisko Therapeutics Co, Ltd

INDUSTRY